GTB-3650 TriKE ® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; initial Phase 1 data expected later in 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q4 2025; recent peer-reviewed publication... Read More